Scarica l'app Stockscreener
1.09
11.75%
0.1146
Dopo l'orario di chiusura:
1.13
0.04
+3.67%
Precedente Chiudi:
$0.9754
Aprire:
$0.99
Volume 24 ore:
1.04M
Relative Volume:
1.01
Capitalizzazione di mercato:
$97.40M
Reddito:
-
Utile/perdita netta:
$-23.49M
Rapporto P/E:
-3.1714
EPS:
-0.3437
Flusso di cassa netto:
$-24.59M
1 W Prestazione:
+23.84%
1M Prestazione:
+3.81%
6M Prestazione:
-40.44%
1 anno Prestazione:
+184.37%
Intervallo 1D:
$0.98
$1.105
Intervallo di 1 settimana:
$0.8532
$1.105
Portata 52W:
$0.2223
$3.83
Cognition Therapeutics Inc Stock (CGTX) Company Profile
Nome
Cognition Therapeutics Inc
Settore
Industria
Telefono
412-481-2210
Indirizzo
2500 WESTCHESTER AVE, PURCHASE
Compare CGTX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CGTX
Cognition Therapeutics Inc
|
1.09 | 87.16M | 0 | -23.49M | -24.59M | -0.3437 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-19 | Aggiornamento | B. Riley Securities | Neutral → Buy |
| 2024-07-30 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2021-11-03 | Iniziato | B. Riley Securities | Buy |
| 2021-11-03 | Iniziato | Oppenheimer | Outperform |
Cognition Therapeutics Inc Borsa (CGTX) Ultime notizie
CGTX: Phase III trials for zervimesine in DLB psychosis and Alzheimer's are advancing with strong safety and efficacy data - TradingView — Track All Markets
Cognition Therapeutics Targets Faster DLB Psychosis Path as Zervimesine Nears Late-Stage Plans - Yahoo Finance
Update Report: Can Cognition Therapeutics Inc disrupt its industryQuarterly Trade Summary & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Insider Trends: Whats the fair value of Cognition Therapeutics Inc stockSell Signal & Real-Time Market Sentiment Reports - baoquankhu1.vn
Insider Sell: Can Cognition Therapeutics Inc disrupt its industryPortfolio Gains Summary & Daily Stock Momentum Reports - baoquankhu1.vn
Big Picture: Whats the fair value of Cognition Therapeutics Inc stockQuarterly Trade Report & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Lewy Body Dementia Market: Accelerating Growth and Pipeline Impact by 2034– DelveInsight | Cognition Therapeutics, KeifeRx, Eisai, EIP Pharma, Sun Pharma, Axovant Sciences Ltd., Cognition Therapeutics - Barchart
Lewy Body Dementia Market: Accelerating Growth and Pipeline - openPR.com
Cognition Therapeutics to Present at Needham Virtual Healthcare Conference - Bitget
Cognition Therapeutics, Inc. CEO Lisa Ricciardi to Present at 25th Annual Needham Virtual Healthcare Conference - Quiver Quantitative
CEO to give Alzheimer's, Lewy body drug update on April 13 - Stock Titan
Fed Meeting: What is the PEG ratio of Cognition Therapeutics Inc2026 Outlook & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
CGTX Technical Analysis & Stock Price Forecast - Intellectia AI
CGTX Should I Buy - Intellectia AI
Cognition Therapeutics CEO Issues Letter to Shareholders - The Manila Times
Cognition Therapeutics plans late-stage trial for dementia drug By Investing.com - Investing.com Australia
Cognition Therapeutics plans late-stage trial for dementia drug - Investing.com
Cognition Plunges 21.8% on Intraday Carnage — What’s Triggering This Sharp Drop? - Bitget
Q1 Earnings Forecast for CGTX Issued By HC Wainwright - MarketBeat
Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation - Sahm
Cognition Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView — Track All Markets
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Cognition Therapeutics (NASDAQ:CGTX) Receives Buy Rating from Chardan Capital - MarketBeat
Cognition Therapeutics posts narrower 2025 loss, eyes DLB trial By Investing.com - Investing.com South Africa
Cognition Therapeutics Reports 2025 Financial Results and Advances Zervimesine for DLB Psychosis and Alzheimer’s Clinical Trials - Minichart
Cognition Therapeutics Inc (CGTX) Q4 2025 Earnings Call Highlights: Promising Developments in ... By GuruFocus - Investing.com Canada
Cognition Therapeutics Advances Zervimesine (CT1812) for Alzheimer’s and Dementia—Clinical Results, Pipeline, and Strategic Overview - Minichart
Cognition Therapeutics Highlights 2025 Results, Zervimesine Progress - TipRanks
Cognition Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
Earnings Call Summary | Cognition Therapeutics(CGTX.US) Q4 2025 Earnings Conference - 富途牛牛
Cognition Therapeutics Q4 Earnings Call Highlights - MarketBeat
Cognition Therapeutics (NASDAQ:CGTX) Posts Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
Earnings call transcript: Cognition Therapeutics Q4 2025 shows reduced losses - Investing.com
Cognition Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
CGTX: Zervimesine advances toward DLB psychosis registration, with strong data and solid cash position - TradingView
Earnings call transcript: Cognition Therapeutics Q4 2025 shows reduced losses By Investing.com - Investing.com South Africa
CGTX: Zervimesine advances for DLB psychosis with strong data, regulatory focus, and improved 2025 financials - TradingView
Cognition Therapeutics posts narrower 2025 loss, eyes DLB trial - Investing.com
COGNITION THERAPEUTICS ($CGTX) Releases Q4 2025 Earnings | CGTX Stock News - Quiver Quantitative
Cognition Therapeutics 10-K: Net loss $23.5M, EPS $(0.32) - TradingView
Zervimesine pipeline and grant backing at Cognition (NASDAQ: CGTX) - Stock Titan
Cognition Therapeutics (NASDAQ: CGTX) narrows 2025 loss, funds into Q2 2027 - stocktitan.net
Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update - The Manila Times
Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical ... - Caledonian Record
Earnings Scheduled For March 26, 2026 - Benzinga
Cognition Therapeutics (CGTX) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Cognition Therapeutics Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results - The Globe and Mail
Cognition Therapeutics sets March 26 webcast on 2025 results - Stock Titan
Cognition Therapeutics Inc Azioni (CGTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.69%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):